Roche drug cocktail doubles chance of holding lung cancer at bay
Fri, Dec 08, 2017 - 5:50 AM
Zurich
ADDING Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome that some experts labelled as unprecedented.
Thirty-seven per cent of patients in a closely watched clinical...
Register to read this article. Log in if you are already a subscriber.Register to read this article. Log in if you are already a subscriber.Please log in or subscribe to continue reading.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes